CDKN2A and renal cell carcinoma: Increased CDKN2A associated with improved OS in mUC (HR = 0.61, p < 0.01) and NSCLC (HR = 0.54, p = 0.03), and trended to improved PFS in RCC (HR 0.78, p = 0.34).